MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar djkumquat (< 20) Submitted: 1/28/2011 11:42:14 AM : Outperform Start Price: $5.11 MNKD Score: -69.42

insider buy on bad news.

Featured Broker Partners


Advertisement